These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2501670)

  • 1. Dramatic response of pulmonary metastasis from prostatic cancer to LH-RH agonist treatment.
    Heyman J; Leiter E
    Mt Sinai J Med; 1989 Mar; 56(2):108-10. PubMed ID: 2501670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
    Behrakis P; Koutsilieris M
    Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
    Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
    Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
    J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Marked effectiveness of the LH-RH analogue in a case of prostate cancer with large lymph node metastasis].
    Takezawa Y; Ohtake N; Nakano K; Uchida T; Okamura K; Yamanaka H
    Hinyokika Kiyo; 1994 Aug; 40(8):721-4. PubMed ID: 7942372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of prostatic cancer with an LH-RH analog].
    Fuse H; Zama S; Akimoto S; Shimazaki J; Murakami S; Igarashi T
    Hinyokika Kiyo; 1986 Aug; 32(8):1113-9. PubMed ID: 3098063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostatic cancer with cystic formation: a case report].
    Kubo M; Taguchi K; Fujisue H; Ihara H; Ikoma F
    Hinyokika Kiyo; 1998 Dec; 44(12):883-6. PubMed ID: 10028435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Total androgen blockade for prostate cancer].
    Kagebayashi Y; Ozono S; Takashima K; Yoshikawa M; Hayashi Y; Kaneko Y; Maruyama Y; Hirao Y; Okajima E
    Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
    Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot.
    Shimizu T; Shibata Y; Uchida T; Satoh J
    Hinyokika Kiyo; 1993 Oct; 39(10):953-5. PubMed ID: 8266863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766).
    Koutsilieris M; Ackman CF
    Prostate; 1987; 10(1):19-24. PubMed ID: 3103114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.